Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02282735 · ClinicalTrials.gov registry record

Parental Decision-Making for Children With Relapsed Neuroblastoma

A clinical trial of Relapsed Neuroblastoma, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
96
Enrollment target
9
Study locations

NCT02282735 is a study of Relapsed Neuroblastoma that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 96 participants, above the 44-participant average among 8 other Relapsed Neuroblastoma trials with a reported enrollment target (118% higher). The trial reports 9 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02282735, a study of Relapsed Neuroblastoma, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
96 participants
Enrollment target
9
Study locations

Study Summary

Parental decision-making for children with advanced cancer is complex. Many parents have overly optimistic beliefs about prognosis and as a result choose aggressive measures even at the end of life, which are associated with greater suffering. Yet most parents wish to limit suffering, and in retrospect, many regret choices for cancer treatment for advanced cancer. These findings suggest that parents do not always have the information they need to make decisions that reflect their preferences. The proposed study will evaluate parental decision-making in advanced cancer, addressing gaps in the literature in 3 important respects. 1) Previous work on decision-making for children with advanced cancer has typically looked at decisions at one point in time, often asking parents to reflect on decisions after the child's death, even though parents' understanding of prognosis and decisions about care evolve over time. We will evaluate parental decision-making for advanced cancer over time. 2) Existing work focuses on aggressive end-of-life care as the worst possible outcome. However, some parents wish to pursue aggressive measures even when they recognize that the child has little chance for cure. We will evaluate the extent to which parental decision-making is informed and consonant with preferences, regardless of whether decisions lead to aggressive or palliative care. 3) Previous studies have focused on groups of different childhood cancers, making it difficult to ascertain whether differences in decision-making reflect differences in diseases, options for care, or parent preferences. We will focus on a single disease, relapsed neuroblastoma, as a model for parental decision-making.

Conditions Studied

Study Locations (9)

California

  • Children's Hospital of Los Angeles - Los Angeles
  • Stanford/Packard's Children's Hospital - Palo Alto

Illinois

  • The University of Chicago Medical Center - Chicago

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New York

  • Columbia University Medical Center - New York

Pennsylvania

  • The Children's Hospital of Philadelphia - Philadelphia

Tennessee

  • St. Jude Children's Research Hospital - Memphis

Texas

  • Cook's Children's Healthcare System - Fort Worth

Washington

  • Seattle Children's Hospital - Seattle

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2013-05
Est. Completion 2027-06

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT02282735

The ClinicalTrials.gov registry entry for NCT02282735 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 8 other Relapsed Neuroblastoma trials with a reported enrollment target (118% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsed Neuroblastoma appearing as the primary indexed condition, and to 0 interventions.

NCT02282735 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02282735 about?

NCT02282735 is a clinical study titled "Parental Decision-Making for Children With Relapsed Neuroblastoma". Parental decision-making for children with advanced cancer is complex. Many parents have overly optimistic beliefs about prognosis and as a result choose aggressive measures even at the end of life, which are associated with greater suffering. Yet most parents wish to limit suffering, and in retrosp...

What is the current status of trial NCT02282735?

This trial is currently active not recruiting. The enrollment target is 96 participants. The study started on 2013-05. Estimated completion is 2027-06.

What conditions does trial NCT02282735 study?

This clinical trial studies the following conditions: Relapsed Neuroblastoma.

Who is sponsoring clinical trial NCT02282735?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02282735 being conducted?

This trial has 9 study locations across California, Illinois, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Relapsed Neuroblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.